GB0003159

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed P. Mahoney

Dated 22 August 2000

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

nts Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

PC/GOW/AM/PO9265GB

2. Patent application number
(The Patent Office will fill in this part)

9919604.0 18 AUG 1999

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

Q-ONE BIOTECH LIMITED
TODD CAMPUS
WEST OF SCOTLAND SCIENCE PARK
GLASGOW
G20 OXA

Patents ADP number *(if you know it)*

6600234700 1

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM

4. Title of the invention

RETROVIRUS ASSAY

5. Name of your agent *(if you have one)*

CRUIKSHANK & FAIRWEATHER
19 ROYAL EXCHANGE SQUARE
GLASGOW
G1 3AE

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

Patents ADP number *(if you know it)*

547002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body. See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	
Description	36
Claim(s)	8
Abstract	
Drawing(s)	4

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature Cruikshank & Fairweather Date 18. 08. 1999

CRUIKSHANK & FAIRWEATHER

12. Name and daytime telephone number of person to contact in the United Kingdom

DR PAUL CHAPMAN
0141 221 5767

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

RETROVIRUS ASSAY

The present invention relates *inter alia* to porcine endogenous retrovirus (PoERV) fragments, in particular to *gag* and *env* fragments of PoERV. The invention relates further to use of such fragments in detection of PoERV or detection of exposure to PoERV. There is also provided antibodies to *gag* and *env* polynucleotides and polypeptides; kits for the detection of PoERV or exposure to PoERV; and *env* peptides and antisera specific for the various types of PoERV and use of such peptides and antisera in the detection of specific PoERV types.

Porcine endogenous retrovirus (PoERV) is an endogenous Gammaretrovirus present typically as a provirus found in several loci in the porcine genome. The proviral genome can be silent or is expressed. Expression of the virus was found to be associated with leukaemic pigs (Strandstrom et al, 1974) and some continuous porcine cell lines produce PoERV (Todaro et al, 1974). Virus from these cells has been shown to infect non-porcine cell-types including human cells (Galbraith et al, 1997; Patience et al, 1997). Three subgroups of PoERV have been described and are designated PoERV A, B and C dependent on the tropism of the virus and the related envelope gene structure (Onions et al, 1998). Only subtypes A and B have been shown to be capable of consistently infecting human cells in vitro. Subgroup C PoERV from mini-pigs has only been shown to infect one

human cell line and this may reflect a low capacity for infection of human cells. Since PoERV is expressed in pigs there is the potential for virus to be present in material prepared from pigs. Furthermore, as a consequence of xenotransplantation using porcine donor organs, there is the possibility that the endogenous virus will be expressed in vivo and be a potential risk of PoERV infection of the patient and the general population thereafter.

The risk of PoERV infection to humans is unknown and as a precaution clinical trial recipients of porcine tissue are monitored for evidence of viral infection by both polymerase chain reaction based methods and immunological methods. Exposure of patients to porcine tissue expressing PoERV viral antigens or infection by PoERV virions is likely to lead to an immune response and subsequently circulating antibodies to these proteins. Screening of serum from recipients of porcine tissue for antibodies to PoERV allows a rapid diagnosis of exposure to viral antigens and a potential infectious state. The screening can include detection of circulating viral antigen or expression of viral antigens in tissues. A number of techniques can be used for this screening.

A number of different types of PoERV are known, based on their genetic makeup. Types designated PERV A, PERV B, and PoEV1 are described in International Patent Application WO97/40167, while types designated PERV MSL and Tsukuba are described in International Patent Application WO97/21836.

PoERV viruses comprise three genes: *gag*, *pol*, and *env*,

generating GAG, POL and ENV polypeptides. It has been observed that the *gag* region of the genome appears to be substantially conserved among different viruses, as well as between PoERV virus types, while the *env* region contains both conserved and non-conserved regions, which non-conserved regions are observed to vary between viral types.

It is among the objects of the present invention to provide means whereby patients and/or samples may be monitored for viral infection. It is further among the objects of the present invention to provide means whereby the viral type may be determined.

According to one aspect of the present invention there is provided a PoERV polypeptide fragment, wherein said polypeptide fragment has PoERV specific antigenic or immunogenic activity. Antigenic or immunogenic activity is to be understood as capable of eliciting a PoERV specific immune response when introduced into a normal mammalian host. For example, PoERV specific antibodies are produced as a consequence.

According to a further aspect of the present invention there is provided an antiserum specific to a PoERV polypeptide fragment as described above.

According to one aspect of the present invention, there is provided a fragment of a PoERV GAG polypeptide, wherein said fragment has PoERV specific antigenic or immunogenic activity. Such a fragment will b referred to hereinafter as a GAG peptide, it being understood that this is distinct from native GAG protein, and may comprise only

a fragment thereof, provided the GAG peptide has antigenic activity. The consensus PoERV GAG polypeptide sequence is shown in figure 1; in preferred embodiments of the invention, the GAG peptide may be selected from within this sequence.

According to a further aspect of the present invention, there is provided a fragment of a PoERV ENV polypeptide, wherein said fragment has PoERV specifc antigenic or immunogenic activity. Such a fragment will be referred to hereinafter as an ENV peptide, it being understood that this is distinct from native ENV protein, and may comprise only a fragment thereof, provided the ENV peptide has antigenic activity. In one embodiment, the ENV peptide may be selected from within a conserved region of the various PoERV sequences, as illustrated in figures 2 and 3. Conserved regions are those which comprise identical and/or highly conserved amino acid sequences in different PoERV virus types; wholly conserved amino acids are indicated in figures 2 and 3 by an asterisk beneath the amino acid, with highly conserved amino acids being indicated by a colon. Alternatively, the ENV peptide may be selected from within the non-conserved regions of the various PoERV sequences of figures 2 and 3, in which case the ENV peptide will be specific for a particular type of PoERV. Specific examples of non-conserved type-specific ENV peptides are shown as peptides D-H and J in figure 3 In a third embodiment, the ENV peptide may comprise both a conserved and a non-conserved region of the PoERV ENV

protein, from either adjacent or non-adjacent regions of the ENV protein. Such peptides may be considered useful in simultaneous detection of any PoERV virus and a specific viral type.

In a further aspect of the present invention, there is provided a fusion GAG/ENV peptide, which peptide comprises both GAG peptide sequences and ENV peptide sequences. Such peptide may be considered useful in simultaneous detection of any PoERV virus, by means of the GAG peptide, and a specific viral type, by means of the ENV peptide.

According to a yet further aspect of the present invention there is provided antibodies specific to either GAG or ENV peptides. The antibodies may be polyclonal or monoclonal. Such antibodies can include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, $F(ab')_2$ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. The Ig tails of such antibodies can be modified to reduce complement activation and Fc binding, (See, for example, European Patent No. 239400 B1, Aug. 3, 1994).

For the production of antibodies to a peptide, various host animals can be immunized by injection with a peptide, or a portion thereof. Such host animals can include but are not limited to rabbits, mice, and rats, t name but a few. Various adjuvants can be used to increase the immunological response, depending on the host species,

including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Gurein) and *Corynebacterium parvum*.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as target gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, can be immunized by injection with a gene product supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique of Kohler and Milsrein, (1975, Nature 256:495-497; and US Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Anti-bodies And Cancer Therapy, Alan R. Liss, Inc., pp.77-96).

Such antibodies can be of any immunoglobulin class

including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention can be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

In addition, techniques for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454; U.S. Pat. No. 4,816,567) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778: Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) and for making humanized monoclonal antibodies (U.S. Pat. No. 5,225,539) can be utilized to produce anti-differentially expressed or anti-pathway gene product antibodies.

Antibody fragments which recognize specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to: the $F(ab')_2$

fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Further aspects of the present invention provide methods of screening serum or tissue from humans or animal recipients of porcine tissue for exposure to PoERV. These methods include: use of antibodies to GAG or ENV peptides in the capture and/or detection of PoERV antigens; use of antibodies to GAG or ENV peptides in the detection of PoERV gene expression in virus infected cells by indirect immunofluorescence staining; the use of antibodies to GAG or ENV peptides in the visualisation of PoERV virions in a sample by immuno-electron microscopy; use of GAG or ENV peptides in Western blotting for the detection of PoERV antibodies in samples from recipients of porcine-derived materials; and the use of GAG or ENV peptides in an enzyme-linked immunosorbent assay (ELISA) for the detection of PoERV antibodies.

Each of these methods may non-specifically detect any PoERV type (if GAG peptides, conserved ENV peptides or antibodies are used) or specific PoERV types, if type-specific non-conserved ENV peptides or antibodies are used.

The present invention also encompasses assay kits including GAG or ENV peptides or antibodies to such

peptides, for use in the abovementioned assays. In preferred embodiments, the kits may further comprise any or all necessary preparative reagents, washing reagents, detection reagents and signal producing reagents commonly known in the art.

In all of these assays and methods, a number of distinct peptides or antibodies may be used, either sequentially or simultaneously, and differently labelled, in order to detect a number of different PoERV types in a single assay.

Diagnostic assays based upon the present invention may be used to determine the presence or absence of PoERV infection, and the PoERV type involved.

In an assay for the diagnosis of viral infection, there are basically three distinct approaches that can be adopted, involving the detection of viral nucleic acid, viral antigen or viral antibody respectively. Viral nucleic acid is generally regarded as the best indicator of the presence of the virus itself and would identify materials likely to be infectious. However, the detection of nucleic acid is not usually as straightforward as the detection of antigens or antibodies since the level of target can be very low. Viral antigen is used as a marker for the presence of virus and as an indicator of infectivity. Depending upon the virus, the amount of antigen present in a sample can be very low and difficult to detect. Antibody detection is relatively straightforward because, in effect, the host immune system

is amplifying the response to an infection by producing large amounts of circulating antibody. The nature of the antibody response can often be clinically useful, for example IgM rather than IgG class antibodies are indicative of a recent infection, or the response to a particular viral antigen may be associated with clearance of the virus. Thus the exact approach adopted for the diagnosis of a viral infection depends upon the particular circumstances and the information sought. In the case of PoERV, a diagnostic assay may embody any one or a combination of these three approaches.

In an assay for the diagnosis of PoERV involving detection of viral antigen or antibody, the method may comprise contacting a test sample with a peptide of the present invention or a polyclonal or monoclonal antibody against the peptide and determining whether there is any antigen-antibody binding contained within the test sample. For this purpose, a test kit may be provided comprising a peptide, as defined herein, or a polyclonal or monoclonal antibody thereto and means for determining whether there is any binding with antibody or antigen respectively contained in the test sample to produce an immune complex. The test sample may be taken from any appropriate tissue or physiological fluid, such as blood (e.g. serum or plasma), saliva, urine, cerebrospinal fluid, sweat, tears or tissue exudate. If a physiological fluid is obtained, it may optionally be concentrated for any viral antigen or antibody present.

A variety of assay formats may be employed. The peptide can be used to capture selectively antibody against PoERV from solution, to label selectively the antibody already captured, or both to capture and label the antibody. In addition, the peptide may be used in a variety of homogeneous assay formats in which the antibody reactive with the peptide is detected in solution with no separation of phases.

The types of assay in which the peptide is used to capture antibody from solution involve immobilization of the peptide on to a solid surface. This surface should be capable of being washed in some way. Examples of suitable surfaces include polymers of various types (moulded into microtitre wells; beads; dipsticks of various types; aspiration tips; electrodes; and optical devices), particles (for example latex; stabilized red blood cells; bacterial or fungal cells; spores; gold or other metallic or metal-containing sols; and proteinaceous colloids) with the usual size of the particle being from 0.02 to 5 microns, membranes (for example of nitrocellulose; paper; cellulose acetate; and high porosity/high surface area membranes of an organic or inorganic material).

The attachment of the peptide to the surface can be by passive adsorption from a solution of optimum composition which may include surfactants, solvents, salts and/or chaotropes; or by active chemical bonding. Active bonding may be through a variety of reactive or activatable functional groups which may be exposed n the surface (for

example condensing agents; active acid esters, halides and anhydrides; amino, hydroxyl, or carboxyl groups; sulphydryl groups; carbonyl groups; diazo groups; or unsaturated groups). Optionally, the active bonding may be through a protein (itself attached to the surface passively or through active bonding), such as albumin or casein, to which the viral peptide may be chemically bonded by any of a variety of methods. The use of a protein in this way may confer advantages because of isoelectric point, charge, hydrophilicity or other physico-chemical property. The viral peptide may also be attached to the surface (usually but not necessarily a membrane) following electrophoretic separation of a reaction mixture, such as immunoprecipitation.

After contacting the surface bearing the peptide with a test sample (in the presence of a blocking mixture if required), allowing time for reaction, and, where necessary, removing the excess of the sample by any of a variety of means, (such as washing, centrifugation, filtration, magnetism or capillary action) the captured antibody is detected by any means which will give a detectable signal. For example, this may be achieved by use of a labelled molecule or particle as described above which will react with the captured antibody or any molecule containing an epitope contained in the peptide. In one embodiment, it is preferred to add an anti-human IgG conjugated to horseradish peroxidase and then to detect the bound enzyme by reaction with a substrate to generate a

colour.

The detectable signal may be produced by any means known in the art such as optical or radioactive or physico-chemical and may be provided directly by labelling the molecule or particle with, for example, a dye, radiolabel, fluorescent, luminescent, chemiluminescent, electroactive species, magnetically resonant species or fluorophore, or indirectly by labelling the molecule or particle with an enzyme itself capable of giving rise to a measurable change of any sort. Alternatively the detectable signal may be obtained using, for example, agglutination, or through a diffraction or birefrigent effect if the surface is in the form of particles.

Assays in which a peptide itself is used to label an already captured antibody require some form of labelling of the peptide which will allow it to be detected. The labelling may be direct by chemically or passively attaching for example a radiolabel, magnetic resonant species, particle or enzyme label to the peptide; or indirect by attaching any form of label to a molecule which will itself react with the peptide. The chemistry of bonding a label to the peptide can be directly through a moiety already present in the peptide, such as an amino group, or through an intermediate moiety, such as a maleimide group. Capture of the antibody may be on any of the surfaces already mentioned in any reagent including passive or activated adsorption which will result in specific antibody or immune complexes being bound. In

particular, capture of the antibody could be by anti-species or anti-immunoglobulin-sub-type, by rheumatoid factor, proteins A, G and the like, or by any molecule containing an epitope contained in the peptide.

The labelled peptide may be used in a competitive binding fashion in which its binding to any specific molecule on any of the surfaces exemplified above is blocked by antigen in the sample. Alternatively, it may be used in a non-competitive fashion in which antigen in the sample is bound specifically or non-specifically to any of the surfaces above and is also bound to a specific bi- or poly-valent molecule (e.g. an antibody) with the remaining valencies being used to capture the labelled peptide.

Examples of the invention will now be described by way of illustration only, and with reference to the accompanying figures, in which:

Figure 1 is the consensus amino acid sequence of the PoERV GAG protein;

Figure 2 is a comparision of amino acid sequences of five different PoERV ENV proteins; and

Figure 3 is a comparision of amino acid sequences of the variable region of five different PoERV ENV proteins, showing the six different ENV peptides (peptides D-H and J) referred to in the following examples.

METHODS

Preparation of PoERV virions.

Human 293 cells (American Type Culture Collection [ATCC] # CRL1573) and Raji cells (ATCC # CCL 86) were infected with PoERV by exposure to polybrene (Sigma-Aldrich Co. Ltd.) and continued incubation with cell-free filtered supernatant from PK-15 (ATCC # CCL 33) cells previously shown to be infected with all three subgroups of PoERV. The 293 cells allow replication of type B PoERV (POEV-1). The 293 cells were shown to be infected after passage by measurement of the reverse transcriptase activity of the cell supernatant and by a PoERV GAG-specific Polymerase Chain Reaction (PCR). The resulting virus particles were isolated from the cell line supernatant as follows. Supernatant from exponentially growing cells was layered onto a 20/40% (w/v) discontinuous sucrose density gradient and centrifuged at 100,000 g for 150 min. The viral material at the sucrose interface was harvested, and viral particles pelleted by further ultracentrifugation at 100,000g for 60 min, followed by resuspension in DMEM (Life Technologies Ltd., UK).

Control retroviruses

To provide retroviral controls for cross reactivity with PoERV GAG and ENV, Squirrel monkey retrovirus, Murine leukaemia virus, Maedi-Visna virus and Equine infectious anemia virus virions were prepared from the appropriate

infected cell line as described by Shepherd and Smith (1999).

Selection and preparation of GAG peptides

Peptides from the GAG protein can provide a capture antigen and a means to generate positive control antisera. The antisera can be directed against conserved polypeptides present in the PoERV virion core likely to induce an immune response in recipients of the virus. These reagents would be useful diagnostic tools for immunosurveillance of recipients of porcine material or tissues for exposure to PoERV. Therefore, peptides encompassing potential antigenic regions of PoERV GAG were selected from the translated amino-acids derived from the sequence of the gag region of PoERV based on three criteria; hydrophilicity, potential ß-turns and K, D, R and E charged residues. The regions were identified using Hopp and Woods hydropathicity (1981) scale and Kyte and Doolittle (1982) hydrophobicity scale.

For GAG two peptides were identified as potential antigens. Peptide 1 was from the C-terminus of p30-GAG at residue 437-451 of the polypeptide, nucleotides 1896-1940 of the *gag* open reading frame (ORF). Peptide 2 was from the start of the p10 segment of the GAG polypeptide at residue 502-515 of the polypeptide, nucleotides 2091- 2132 of the *gag* ORF. The peptides shown below were chemically synthesised by Genosys Biotechnologies Inc.

Peptide 1: (C)REERRDRRQEKNLTK

Peptide 2: (W)ARNCPKKGNKGPKS

The bracketed amino-acid is not in sequence - 5' position is from next residue (R).

These peptides, and the GAG consensus polypeptide sequence, are shown in figure 1.

A BLAST search (Altschui et al., 1997) of the non-redundant GenBank coding sequences with GAG peptide 1 showed homology with seven sequences all from the *gag* ORF. Of the seven, three were with PoERV sequences with accessions gi 3116446 (100% match), emb CAA7651 (100% match), gi 3116442 (86% match). The remainder were against the closely related Gibbon ape leukaemia virus (gi 3033415, 92% match) and Simian sarcoma virus (sp PO3330, 86% match). The remaining two sequences were from murine viruses, including a virus from *Rattus norvegicus* (emb CAA24514; 92% match), and one against *Mus dunni* endogenous retrovirus (gi 3309124, 93% match). A similar BLAST search with GAG peptide 2 showed 100 - 99% homology with only the PoERV sequences listed above.

Selection and Preparation of PoERV ENV peptides

We have previously identified and derived the nucleotide sequence of a unique PoERV type capable of infecting human cells (Galbraith, 1997). Furthermore, it has been shown that the amino acid sequence of the ENV region of various

PoERV types contains both conserved and non-conserved regions (Galbraith, 1997; Figure 2). In order to exploit these differences to produce immunological reagents to allow the identification of the type of PoERV giving rise to an immunological reaction in a patient, PoERV-type-specific ENV peptides and antisera were generated.

Six peptides, D-H and J, were identified as potential antigens. The peptides are shown below and their position in the *env* ORF of the various PoERV types is shown in Figure 3. The peptides were chemically synthesised by the University of Glasgow Veterinary Pathology Department.

Peptide D: TSLRPDITQPPSNSTT

Peptide E: KGKQENIQKWINGMS

Peptide F: RKTGKYSKVDKWYELGNS

Peptide G: NTVLTGQRPPTQ

Peptide H: GHGRWKDWQQRVQKDVRNKQIS

Peptide J: IQEQRPSPNPSDYNTT

The amino acid residues of all peptides are identified by the standard one letter abbreviations.

Preparation of recombinant PoERV p30-GAG and ENV polypeptides

In addition to the peptide reagents more general PoERV p30-GAG and an abbreviated ENV polypeptides were designed and produced for use as capture antigens and to produce anti-polypeptide sera. The required polypeptide portions of the

gag and *env* genes were produced by PCR amplification, molecularly cloned into a prokaryotic expression vector and expressed as described below using standard techniques (Maniatis et al, 1982).

PoERV p30-GAG

A fragment encompassing the p30 region of the *gag* ORF from nucleotide 1173-1949 of the PoERV genome (Galbraith et al, 1997; Gene Bank Accession # A66553) was amplified by PCR from cDNA generated from PK15 mRNA using ligation independent cloning oligonucleotide primers (pET-32 Ek/LIC cloning and expression vector; Novagen Inc. Catalogue # 69076-3). The oligonucleotides were:

p30 forward 5' GAC GAC GAC AAG **CTG CGC ACC TAT GGC C** 3'

p30 reverse 5' GAG GAG AAG CCC GGG **TCT AGG CCA AGA TCT TAG TCA AAT TCT TCT C** 3'

The nucleotides in bold are viral specific.

The PCR conditions were 30 cycles of 95°C for 1 min, 58°C for 1 min and 72°C for 1 min. The resulting 776 base pair fragment was molecularly cloned into the appropriate LIC site of the pET-32 LIC vector following the manufacturer's instructions (Novagen Inc. 69076-3 instruction manual), transfected into competent Novoblue™

Escherichia coli cells and plated on solid LB medium containing ampicillin. The transformed colonies were selected by resistance to ampicillin.

PoERV ENV

A fragment encompassing the region of the *env* ORF from nucleotide 5616- 6304 of the PoERV genome (Galbraith et al,1997; Gene Bank Accession # A66553) was amplified by PCR from cDNA generated from PK15 and PoERV-infected 293 cells (PoERV B) mRNA using ligation independent cloning oligonucleotide primers (pET-32 Ek/LIC cloning and expression vector; Novagen Inc. Catalogue # 69076-3). The oligonucleotides were:

env forward 5' **GAC GAC GAC AAG ATC CAT GCA TCC CAC GTT** 3'

env reverse 5' **GAG GAG AAG CCC GGT CTC TAT CCT AAG GCG** 3'

The nucleotides in bold are viral specific.

The PCR conditions were 30 cycles of 95°C for 1 min, 60°C for 1 min and 72°C for 1 min. The resulting 688 base pair fragment was molecularly cloned into the appropriate LIC site of the pET-32 LIC vector following the manufacturer's instructions as described above.

For expression from the T7 promoter the recombinants

are required to be transferred to a host with T7 polymerase activity. To this end plasmid DNA was isolated from the ampicillin resistant Novoblue™ clones carrying the *gag* or *env* fragment in the correct orientation for expression as determined by restriction endonuclease mapping. The plasmid DNAs were each transfected into competent *E. coli* AD494 (DE3) *trx B-* .

For screening for the production of recombinant protein, two ml cultures of *E. coli* transformed with either of the two expression constructs were grown with shaking at 37°C to late log phase ($O.D._{600nm}$ of approximately 0.6) and induced by the addition of Isopropylthio-beta-galactoside (IPTG) to 0.1 mM. Induced cultures were then incubated for a further 2 h after which the bacteria were collected by centrifugation. The bacterial pellet was lysed by boiling in SDS-PAGE sample buffer and the protein profile of the induced bacteria was analysed on a 12% acrylamide gel followed by staining with coomasie brilliant blue dye. (Laemmli, 1970; Gallagher, 1997).

Large scale preparations of purified GAG and ENV polypeptides were made according to the manufacturer's instructions (Novagen Inc. Catalogue # 69076-3).

Preparation of antisera to whole virions, peptides and recombinant P30-GAG and ENV antigens.

For GAG peptide 1 and peptide 2, the peptides were conjugated with keyhole limpet hemacyanin carrier protein and each of two rabbits was inoculated six times at

fourteen day intervals. The animals were bled out at day seventy seven after the first inoculation. The p30-GAG polypeptide was inoculated three times at fourteen day intervals into a rabbit. The animal was bled out at day seventy seven.

For ENV peptides D-H and J, the peptides were conjugated with keyhole limpet hemacyanin carrier protein and one sheep was inoculated three times at twenty eight day intervals. The ENV polypeptide was inoculated three times at fourteen day intervals into a rabbit.

Virions purified from PK15 cells were inoculated three times at fourteen day intervals into each of two guinea pigs.

Indirect immunofluorescence staining

To test the specificity of the p30-GAG antisera the method outlined by Riggs (1989) was used. PoERV-infected Raji cells and uninfected control Raji cells were fixed and tested for indirect immunofluorescence with anti p30-GAG using a fluorescein isothiocyanate (FITC) labelled anti-rabbit detector antibody. The cells were examined by fluorescence microscopy.

Preparation of Western blot membranes

Recombinant p30-GAG polypeptide and ENV polypeptide were prepared, harvested and purified from an *E.coli* vector. The recombinant proteins were tested to determine an appropriate dilution of protein which yielded a positive

result in the immunoassay. In addition, extracts from PoERV-infected 293 cells, PoERV-infected Raji cells or purified PoERV virions were used as antigens. To obtain specific and reproducible Western blot assays, a number of parameters were required to be optimised for each assay, such as: Primary antibody dilution, incubation time, incubation temperature, secondary antibody dilution, incubation time, incubation temperature, washing buffers, blocking/dilution buffers, developing reagents. Recombinant polypeptides were added to nine wells of a ten lane 12% Tris/glycine acrylamide gel. Molecular weight markers were added to the first lane. The samples were electrophoresed and the gel electroblotted to a poly vinylidene fluoride (PVDF) membrane. (Gallagher et al, 1997). The membrane was cut into strips each strip containing one lane of recombinant protein. These strips were used as the basis of the assay.

Preparation dilutions of antisera

Samples were prepared in a Class 2 safety cabinet or other clean environments.

A typical negative control was prepared by making up to a 1:200 dilution of normal sera in blocking reagent.

A typical positive control was prepared by making a 1: 500, 1: 1000 or greater dilution of anti-P ERV p30-GAG

polypeptide, peptide serum or anti - recombinant ENV serum.

A typical test serum was prepared by making up to a 1:200 dilution of sera.

Preparation of Western blotting membranes and PoERV antibody detection.

To block non-specific binding sites membrane strips each were placed in a 15 ml centrifuge tube and 2 ml blocking reagent (2.5 g skimmed dried milk in 50 ml PBS/ 0.5% v/v Tween-20™) added. The strips were placed on a rotary shaker such that the strip moved slightly on each revolution and were incubated for 30 min at ambient temperature. The blocking reagent was removed and replaced with 5-10 µl of the diluted serum. The membrane was incubated with shaking for 1 h at ambient temperature. To stop incubation the strip was removed from diluted serum and placed into PBS/ Tween-20™ and washed with three changes of PBS/ Tween-20™ at ambient temperature with shaking.

The appropriate species specific secondary antiserum conjugated to alkaline phosphatase was used as detector e.g. if human serum was being tested, an anti-human IgG alkaline phosphatase (AP) conjugate was used. The p30-GAG positive control required anti-rabbit IgG AP conjugate for

detection and the anti ENV required anti-sheep IgG AP conjugate. The detection was done as follows; each strip was placed in an unused 15 ml centrifuge tube, 2 ml of 1:1000 dilution of secondary sera in blocking reagent was added and incubated with shaking at ambient temperature for 1 h. The strip was removed from the centrifuge tube, placed in PBS/Tween-20™ and washed with 3 changes of PBS/Tween-20™, at ambient temperature with shaking. The strips were then put into a 15 ml centrifuge tube and 2 ml of bromochlorindoyl phosphate/ nitroblue tetrazolium (BCIP/NBT, Sigma-Aldrich Co. Ltd.) solution was added to each tube. The strips were shaken gently and allowed to develop for 5 min. The reaction was stopped by rinsing the membrane strip in purified water and the strips were removed from the water and allowed to air dry.

ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)

Antigen coating of microtiter plates

50 µl of antigen (either recombinant p30-GAG, extracts from PoERV-infected 293 cells or purified PoERV B virions) were diluted to the required concentration in carbonate-bicarbonate coating buffer (Sigma-Aldrich Co. Ltd.) was added to wells of a 96 well, flat bottomed microtiter ELISA plate (Dynex Immulon 2). Some wells contained carbonate-bicarbonate coating buffer only and some were left blank to act as controls for non-specific binding. The plate was covered with a plate seal and incubated at 4°C for

approximately 16 h. The unbound antigen and coating solution were then removed from the wells with a pipette and washed three times with PBS / 0.05% Tween-20™. Any remaining PBS / 0.05% Tween-20™ was removed by blotting on a tissue.

Blocking of microtiter plates

50 µl of fresh blocking buffer (5% (w/v) skimmed milk /PBS / 0.05% Tween-20™) was added to each antigen coated well and control well. The plate was covered with a plate seal and incubated at ambient temperature in an humidified chamber for 1 h. The blocking buffer was removed and the plate wells washed three times with PBS / 0.05% Tween-20™ and any remaining PBS / 0.05% Tween-20™ was removed by blotting on a tissue.

Incubation with primary antibody

50 µl of negative control sera, test sera, and positive control sera at the experimental dilution were added to the antigen coated wells and the plates covered with a plate seal and incubated at ambient temperature for approximately 1 h in an humidified chamber. Following incubation all sera were removed using a pipette and the plate wells washed three times with PBS / 0.05% Tween-20™, any remaining PBS / 0.05% Tween-20™ was removed by blotting on a tissue.

Incubation and development with peroxidase-conjugat d secondary antibody

50 µl of a 1:500 dilution of species specific peroxidase conjugated secondary antibody in blocking buffer was added to each antigen coated well. For human serum an anti-human IgG peroxidase conjugate was used. The p30-GAG positive control required anti-rabbit IgG peroxidase conjugate for detection and the anti ENV required anti-sheep IgG peroxidase conjugate. The plates were covered with a plate seal and incubated at ambient temperature for approximately 1 h in an humidified chamber. Following incubation the conjugate was removed using a pipette and the plate wells washed three times with PBS / 0.05% Tween-20™. Any remaining PBS / 0.05% Tween-20™ was removed by blotting on a tissue.

The substrate was prepared as follows: one O-phenylenediamine tablet (Sigma-Aldrich Co. Ltd.) and one urea/H_2O_2 tablet were dissolved in 20 ml of purified water. An aliquot of 50 µl of substrate was added to each well and the plate incubated at ambient temperature in the dark for 30 min. The reaction was then stopped by adding 50 µl of 3N HCl or 3 M H_2SO_4 to each well. The colour development in the wells was measured at 490 nm using a Dynex MRX microplate reader.

For alkaline phosphatase conjugated secondary antibodies the substrate used was p-Nitrophenyl phosphate (pNPP; Sigma-Aldrich Co. Ltd.) and the plates were read at 405 nm.

Electron Microscopy

Negative stain electron microscopy (NSEM) (Doane, 1980) was used to identify the presence of PoERV virions. Supernatant from PoERV-infected pK15 cells was layered onto a 20/40% (w/v) discontinuous sucrose density gradient and centrifuged at 100,000 g for 150 min. The viral material at the sucrose interface was harvested, and viral particles pelleted by further ultracentrifugation at 100,000g for 60 min, followed by resuspension in DMEM (Life Technologies Ltd.). The sample was then applied to pioloform-coated copper 300 mesh EM grids and allowed to air dry. Grids were fixed with 2.5% glutaraldehyde (Agar Scientific), stained with 5% uranyl acetate (Agar Scientific) and allowed to air dry. Grids were examined on a Philips EM-400 transmission electron microscope.

Immuno- Electron Microscopy

The immunostaining was done following the method of Marshall et al (1992). Briefly, NSEM samples were applied to pioloform-coated nickel 300 mesh EM grids and allowed to air dry. Grids were fixed with modified immunofix, post fixed with 0.5 M NH_4Cl, then incubated with 2% bovine serum albumin (Sigma-Aldrich Co. Ltd.). Samples were then incubated with rabbit anti-PoERV (rabbits immunised with whole PoERV) or rabbit anti-PoERV p30-GAG antibody, washed in modified immunobuffer followed by incubation with anti-rabbit IgG gold conjugate (Sigma-Aldrich Co. Ltd.). Grids were stained with 5% uranyl acetate, and allowed to air

dry. Samples were visualised on a Philips EM-400 transmission electron microscope.

EXAMPLE ONE

Indirect immunofluorescence staining of PoERV-infected cells.

Viral specific fluorescence was observed in PoERV-infected Raji cells using the anti p30-GAG antiserum. No immunofluorescence was seen with the negative control Raji cells.

EXAMPLE TWO

Western Blotting for Antibodies to PoERV GAG

Anti-GAG peptide 1 antisera and sera from rabbits inoculated with the recombinant p30-GAG polypeptide detected the expected protein of approximately 30kd in extracts of PoERV-infected 293 or PoERV-infected Raji cells, purified PoERV virions and recombinant p30-GAG. The PoERV antibody could be detected at a dilution of 1:1000.

No band of equivalent size to the GAG 30 kd polypeptide was detected in uninfected control cells.

No band of equivalent size to the GAG 30 kd polypeptide was detected against the following purified retroviruses:

Squirrel monkey retrovirus

Murine leukaemia virus

Maedi-Visna virus

Equine infectious anemia virus

Therefore, the positive control antisera were specific for PoERV.

Determination of assay specificity using Serum Panels

Normal human sera

On testing of 90 normal serum samples from healthy individuals, whose blood was taken for occupational health reasons, no PoERV reactive antibody was detected in any of the sera.

Normal primate sera

On testing 42 normal serum samples from healthy primates no PoERV reactive antibody was detected. There was no cross-reactivity with sera from normal primates.

Cardiac transplant patient sera

On testing 20 serum samples from individuals who had received a cardiac transplant in the preceding 36 months no PoERV reactive antibody was detected. There was no cross-reactivity with sera from patients who had been immunosupressed.

HIV positive sera

On testing 13 serum samples from individuals positive for the presence of antibody to HIV no PoERV reactive antibody was detected. There was no cross-reactivity with sera from patients infected with a human Lentivirus.

HTLV postive sera

On testing 10 serum samples from individuals positive for the presence of antibody to HTLV-1 virus no PoERV reactive antibody was detected. There was no cross-reactivity with sera from patients infected with a human Gammaretrovirus.

Butchers with acute lymphoblastic leukaemia (ALL)

On testing 3 serum samples from butchers with ALL no PoERV reactive antibody was detected. There was no cross-reactivity with sera from patients with assumed prolonged exposure to PoERV and PoERV antigens with a leukaemic disorder.

EXAMPLE THREE

ELISA p30-GAG

A titration of p30-GAG antigen to anti-p30-GAG antisera gave a significant signal at 1:250600 dilution antigen to 1:32000 dilution of antisera. A similar titration of antisera against PoERV virions gave a significant signal at

a 1:3200 dilution of both antigen and antisera.

Normal human sera

On testing of five normal serum samples from healthy individuals whose blood was taken for occupational health reasons, no significant signal was detected in any of the sera against recombinant p30-GAG.

EXAMPLE FOUR

Detection and Visualisation of PoERV Virions by Immuno-Electron Microscopy

Examination of PoERV virion preparations by negative stain revealed particles showing the characteristic size and structure of a Gammaretrovirus of approximately 90-120 nm with a dark inner core and double membraneous outer region. The particles bound immuno-gold labeled anti p30-GAG antiserum indicating that the antiserum could be used to visualise PoERV virions by immuno-electron microscopy.

EXAMPLE FIVE

ELISA ENV

A titration of antisera raised against ENV peptides D, E, F, G, H, J. to purified PoERV B virions gave a significant signal indicating that the ENV peptides produced a virus-specific reaction in the animals. Peptides D and F, both from PoERV B (POEV1; Figure 2; Galbraith et al, 1997) gave the highest signal.

EXAMPLE SIX

Western Blotting for Antibodies t PoERV ENV

Antisera from guinea pigs inoculated with whole purified PoERV virions from PK15 cells detected the expected recombinant ENV protein of approximately 24 kD in extracts of *E.coli* expressing the *env* construct.

No band of equivalent size to the ENV 24 kD polypeptide was detected on *E.coli* control cells without the expresion construct.

REFERENCES

Altschui SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research, 25: 3389-3402.

Doane FW . (1980). Virus morphology as an aid for rapid diagnosis. Yale Journal of Biological Medicine, 53, 19-25.

Ekins RP. (1997). Immunoassay design and optimisation. In Principles and Practice of Immunoassay Second Edition. Ed. CP Price and DJ Newman. Macmillan Reference, Ltd. London.

Fishman JA. (1997). Patent Application WO97/21836.

Galbraith DN. Haworth C, Lees GM, and Smith KT. (1997). Patent Application WO97/40167.

Gallagher S. (1997). One-dimensional SDS gel electrophoresis of proteins. In Current Protocols in Molecular Biology. 10.2.2-10.2.35. John Wiley & Sons, Inc. USA.

Gallagher S, Winston SE, Fuller SA and Hurrell JGR. (1997). Immunoblotting and immunodetection. In Current Protocols in Molecular Biology. 10.8.1-10.8.21. John Wiley & Sons, Inc. USA.

Hopp TP and Woods KR. (1981). Prediction of protein antigenic determinants from amino acid sequences. Proceeding of the National Academy of Sciences USA, 78, 3824-3828.

Kyte J and Doolittle RF. (1982). A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology, 157, 105-132.

Laemmli UK. 1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.

Maniatis T, Fritsch EF and Sambrook J. (1982). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Marshall GE, Kontas AG, Reid GG, Edwards JG and Lee WR. (1992). Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula. British Journal of Ophthalmology, 76, 607-614.

Onions D, Hart D, Mahoney C, Galbraith D and Smith K. (1998). Endogenous retroviruses and the safety of porcine xenotransplantation. Trends in Microbiology, 6, 430-431.

Patience C, Takeuchi Y and Weiss R. (1997). Infection of human cells by an endogenous virus of pigs. Nature

Medicine, 3, 282-286.

Riggs JL. (1989). Immunofluorescence staining. In Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections Sixth Edition. Ed. NJ Schmidt and RW Emmons. 123-133. American Public Health Association Inc. Washington DC.

Strandstrom H, Veijalainen P, Moennig V, Hunsmann G, Schwarz H and Schafer W. (1974). C-type particles produced by a permanent cell line from a leukemic pig. 1. Origin and properties of the host cells and some evidence for the occurrence of C-type particles. Virology, 57, 175-178.

Shepherd AJ and Smith KT. (1999). Viral evaluation of animal cell lines used in biotechnology. In Methods in Biotechnology, Vol. 8: Animal Cell Biotechnology. Ed. N Jenkins. Humana Press, Inc. Totwa New Jersey.

Todaro GJ, Benveniste RE, Lieber MM, and Sher CJ. (1974). Characterisation of a type C virus released from the porcine cell line PK (15). Virology, 58, 65-74.

FIGURE 1

PoERV *GAG* POLYPEPTIDE SHOWING POSITIONS OF PEPTIDES

MGQTVTTPLSLTLDHWTEVRSRAHNLSVQVKKGPWQTFCASEWPTFDVGWPSEGTFNSEIILAVKAIIFQ
TGPGSHPDQEPYILTWQDLAEDPPPWVKPWLNKPRKPGPRILALGEKNKHSAEKVEPSSSYLPRDRGAAD
LAGTPTCSPTPLSSTGCCEGTSAPPGAPVVEGPAAGTRSRRGATPERTDEIAILPLRTYGPPMPGGQLQP
LQYWPFSSADLYNWKTNHPPFSEDPQRLTGLVESLMFSHQPTWDDCQQLLQTLFTTEERERILLEARKNV
PGADGRPTQLQNEIDMGFPLTRPGWDYNTAEGRESLKIYRQALVAGLRGASRRPTNLAKVREVMQGPNEP
PSVFLERLMEAFRRFTPFDPTSEAQKASVALAFIGQSALDIRKKLQRLEGLQEAELRDLVREAEKVYYRR
ETEEEKEQRKEKEREE**reerrdrrqeknltk**ILAAVVEGKSSRERERDFRKIRSGPRQSGNLGNRTPLDK
DQCAYCKEKGHW**arncpkkgnkgpkv**LALEEDKD

Figure 1. The *gag* peptides 1 and 2 are shown in lower case bold. Peptide 1: REERRDRRQEKNLTK; Peptide 2: ARNCPKKGNKGPKS.

FIGURE 2

ALIGNMENT OF DIFFERENT PoERV ENVELOPE PROTEINS

```
PERVA       MHPTLSRRHLPIRGGKPKRLKIPLSFASIAWFLTLSITPQVNGKRLVDSPNSHKPLSLTW
POEVMSL     MHPTLNRRHLPIRGGKPKRLKIPLSFASIAWFLTLSITSQTNGMRIGDSLNSHKPLSLTW
TSUKUBA     MHPTLSRRHLPIRGGKPKRLKIPLSFASIAWFLTLSITSQTNGMRIGDSLNSHKPLSLTW
PERVB       MHPTLSWRHLPTRGGEPKRLRIPLSFASIAWFLTLTITPQASSKRLIDSSNPHRPLSLTW
POEV1       MHPTLSRRHLPTRGGEPKRLRIPLSFASIAWFLTLTITPQASSKRLIDSSNPHRPLSLTW
            *****. ***  :* :****:********:*****:**.*... :: ** * *:******

PERVA       LLTDSGTGININSTQGEAPLGTWWPELYVCLRSVIPGLNDQATPPDVLRAYGFYVCPGPP
POEVMSL     LITDSGTGININNTQGEAPLGTWWPDLYVCLRSVIPSL---TSPPDILHAHGFYVCPGPP
TSUKUBA     LITDSGTGININNTQGEAPLGTWWPDLYVCLRSVIPSL---TSPPDILHAHGFYVCPGPP
PERVB       LIIDPDTGVTVNSTRGVAPRGTWWPELHFCLRLINPAVK--STPPNLVRSYGFYCCPG-T
POEV1       LIIDPDTGVTVNSTRGVAPRGTWWPELHFCLRLINPAVK--STPPNLVRSYGFYCCPG-T
            *: *..**:.::.::* **  ****:*:.*** : *.:   ::.*::: :: *  *** .

PERVA       NNEEYCGNPQDFFCKQWSCITSNDGNWKWPVSQQDRVSYSFVNNPTSYNQFNYGHGRWKD
POEVMSL     NNGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGQFNY-----LT
TSUKUBA     NNGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGQFNY-----LT
PERVB       EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSG--PGKYKVMK-----
POEV1       EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSG--PGKYKMMK-----
            :: :: *.. : * :: .*:*****  *** * ****.:*:**         :

PERVA       WQQRVQKDVRNKQISCHSLDLDYLKISFTE--KGKQENIQKWVNGISWGIVYYGGSGRKK
POEVMSL     W-------IRTGSPKCSPSDLDYLKISFTE--KGKQENILKWVNGMSWGMVYYGGSGKQP
TSUKUBA     W-------IRTGSPKCSPSDLDYLKISFTE--KGKQENILKWVNGMSWGMVYYGGSGKQP
PERVB       ---------LYKDKSCSPSDLDYLKISFTE--KGKQENIQKWINGMSWGIVFYKYGGG-A
POEV1       ---------LYKDKSCSPSDLDYLKISFTERKTGKYSKVDKWY---ELGNSFLLYGGG-A
                  .  * . ***********  . * .:: **    . *  :    .

PERVA       GSVLTIRLRIETQMEPPVAIGPNKGLAEQGPPIQEQRP-SPNPSD----------YNTT
POEVMSL     GSILTIRLKIN-QLEPPMAIGPNTVLTGQRPPTQ-----GPGPS----------SNIT
TSUKUBA     GSILTIRLKIN-QLEPPMAIGPNTVLTGQRPPTQ-----GPGPS----------SNIT
PERVB       GSTLTIRLRIETGTEPPVAVGPDKVLAEQGPPALEPPHNLPVPQLTSLRPDITQPPSNGT
POEV1       GSTLTIRLRIETGTEPPVAMGPDKVLAEQGPPALEPPHNLPVPQLTSLRPDITQPPSNST
            ** *****:*.   ***:*:**:. *: * .*          *.             : *

PERVA       SGSVPT-----EPNITIKTGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
POEVMSL     SGSDPT-----ESNSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
TSUKUBA     SGSDPT-----ESSSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLALGPPYYEGMA
PERVB       TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA
POEV1       TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA
            :   *.     ... . * * :***********:*** *:*********: .****: **

PERVA       RGGKFNVTKEHRDQCTWGSQNKLTLTEVSGKGTCIGMVPPSHQHLCNHTEAFNRTSESQY
POEVMSL     RRGKFNVTKEHRDQCTWGSQNKLTLTEVSGKGTCIGKVPPSHQHLCNHTEAFNQTSESQY
TSUKUBA     RRGKFNVTKEHRDQCTWGSQNKLTLTEVSGKGTCIGKVPPSHQHLCNHTEAFNQTSESQY
PERVB       KEGKFNVTKEHRNQCTWGSRNKLTLTEVSGKGTCIGKAPPSHQHLCYSTVVYEQASENQY
POEV1       KERKFNVTKEHRNQCTWGSRNKLTLTEVSGKGTCIGKAPPSHQHLCYSTVVYEQASENQY
            :  ******:**:******:***********.***  ..******   * .::::**.**

PERVA       LVPGYDRWWACNTGLTPCVSTLVFNQTKDFCVMVQIVPRVYYYPEKAVLDEYDYRYNRPK
POEVMSL     LVPGYDRWWACNTGLTPCVSTLVFNQTKDFCIMVQIVPRVYYYPEKAILDEYDYRNHRQK
TSUKUBA     LVPGYDRWWACNTGLTPCVSTLVFNQTKDFCIMVQIVPRVYYYPEKAILDEYDYRNHRQK
PERVB       LVPGYNRWWACNTGLTPCVSTSVFNQSKDFCVMVQIVPRVYYHPEEVVLDEYDYRYNRPK
POEV1       LVPGYNRWWACNTGLTPCVSTSVFNQSKDFCVMVQIVPRVYYHPEEVVLDEYDYRYNRPK
            *****:**************** ****:*** :**********:*::.:******* :* *
```

```
PERVA           REPISLTLAVMLGLGVAAGVGTGTAALITGPQQLEKGLSNLHRIVTEDLQALEKSVSNLE
POEVMSL         REPISLTLAVMLGLGVAAGVGTGTAALVTGPQQLETGLSNLHRIVTEDLQALEKSVSNLE
TSUKUBA         REPISLTLAVMLGLGVAAGVGTGTAALVTGPQQLETGLSNLHRIVTEDLQALEKSVSNLE
PERVB           REPVSLTLAVMLGLGTAVGVGTGTAALITGPQQLEKGLGELHAAMTEDLRALEESVSNLE
POEV1           REPVSLTLAVMLGLGTAVGVGTGTAALITGPQQLEKGLGELHAAMTEDLRALKESVSNLE
                ::*:***********. .** ******:*******.**.:**  :* :*:**::******

PERVA           ESLTSLSEVVLQNRRGLDLLFLKEGGLCVALKEECCFYVDHSGAIRDSMSKLRERLERRR
POEVMSL         ESLTSLSEVVLQNRRGLDLLFLKEGGLCVALKEECCFYVDHSGAIRDSMNKLRERLEKRR
TSUKUBA         ESLTSLSEVVLQNRRGLDLLFLKEGGLCVALKEECCFYVDHSGAIRDSMNKLRERLEKRR
PERVB           ESLTSLSEVVLQNRRGLDLLFLREGGLCAALKEECCFYVDHSGAIRDSMSKLRERLERRR
POEV1           ESLTSLSEVVLQNRRGLDLLFLREGGLCAALKEECCFYVDHSGAIRDSMNKLRKKLERRR
                :************::*******::  **.****:***************.**:::**::*

PERVA           REREADQGWFEGWFNRSPWMTTLLSALTGPLVVLLLLLTVGPCLINRFVAFVRERVSAVQ
POEVMSL         REKETTQGWFEGWFNRSLWLATLLSALTGPLIVLLLLLTVGPCIINKLIAFIRERISAVQ
TSUKUBA         REKETTQGWFEGWFNRSPWLATLLSALTGPLIVLLLLLTVGPCIINKLIAFIRERISAVQ
PERVB           REREADQGWFEGWFNRSPWMTTLLSALTGPLVVLLLLLTVGPCLINRFVAFVRERVSAVQ
POEV1           REREADQGWFEGWFNRSPWMTTLLSALTGPLVVLLLLLTVGPCLINRFVAFVRERVSAVQ
                **:*: * **: *:*** *::****:*****:*******:***:**:::**:*:*:****

[redacted]VA    IMVLRQQYQGLLSQGETDL
POEVMSL         IMVLRQQYQSPSSR-EAGR
TSUKUBA         IMVLRQQYQSPSSR-EAGR
PERVB           IMVLRQQYQGLLSQGETDL
POEV1           IMVLRQQYQGLLSQGETDL
                *********.  .: *:.
```

Figure 2. Alignment of PoERV envelope genes. The amino acid sequences are derived from the published nucleotide sequences as follows: PERV; PERV A, PERV B, PoEV 1, (Galbraith *et al.*, 1997); PERV MSL, Tsukuba (Fishman, 1997)

FIGURE 3

VARIABLE REGION OF PoERV ENVELOPE POLYPEPTIDE SHOWING POSITIONS OF PEPTIDES

```
PERVA      NNEEYCGNPQDFFCKQWSCITSNDGNWKWPVSQQDRVSYSFVNNPTSYNQFNYghgrwkd
POEVMSL    NNGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGQFNY-----LT
TSUKUBA    NNGKHCGNPRDFFCKQWNCVTSNDGYWKWPTSQQDRVSFSYVNTYTSSGQFNY-----LT
PERVB      EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSG--PGKYKVMK-----
POEV1      EKEKYCGGSGESFCRRWSCVTSNDGDWKWPISLQDRVKFSFVNSG--PGKYKMMK-----

PERVA      wqqrvqkdvrnkqisCHSLDLDYLKISFTE--KGKQENIQKWVNGISWGIVYYGGSGRKK
POEVMSL    W-------IRTGSPKCSPSDLDYLKISFTE--KGKQENILKWVNGMSWGMVYYGGSGKQP
TSUKUBA    W-------IRTGSPKCSPSDLDYLKISFTE--KGKQENILKWVNGMSWGMVYYGGSGKQP
PERVB      ---------LYKDKSCSPSDLDYLKISFTE--kgkqeniqkwingmsWGIVFYKYGGG-A
POEV1      ---------LYKDKSCSPSDLDYLKISFTErktgkyskvdkwy---elgnsFLLYGGG-A

PERVA      GSVLTIRLRIETQMEPPVAIGPNKGLAEQGPPiqeqrp-spnpsd----------yntt
POEVMSL    GSILTIRLKIN-QLEPPMAIGPNTVLTGQRPPTQ-----GPGPS----------SNIT
TSUKUBA    GSILTIRLKIN-QLEPPMAIGPntvltgqrpptq-----GPGPS----------SNIT
PERVB      GSTLTIRLRIETGTEPPVAVGPDKVLAEQGPPALEPPHNLPVPQLTSLRPDITQPPSNGT
POEV1      GSTLTIRLRIETGTEPPVAMGPDKVLAEQGPPALEPPHNLPVPQLtslrpditqppsnst

PERVA      SGSVPT-----EPNITIKTGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
POEVMSL    SGSDPT-----ESNSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLASGPPYYEGMA
TSUKUBA    SGSDPT-----ESSSTTKMGAKLFSLIQGAFQALNSTTPEATSSCWLCLALGPPYYEGMA
PERVB      TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA
POEV1      TGLIPTNTPRNSPGVPVKTGQRLFSLIQGAFQAINSTDPDATSSCWLCLSSGPPYYEGMA
```

Figure 3. The peptides D-H and J are shown in lower case bold. Exact match only is shown. Peptide D:TSLRPDITQPPSNSTT (POEV1); Peptide E:KGKQENIQKWINGMS (PERVB); Peptide F:RKTGKYSKVDKWYELGNS (POEV1); Peptide G: NTVLTGQRPPTQ (TSUKUBA); Peptide H: GHGRWKDWQQRVQKDVRNKQIS (PERVA); Peptide J: IQEQRPSPNPSDYNTT (PERVA).

PCT NO : GB00[redacted]/03159

form 23/77 : 16.8.00

Agent : Cruikshank & Fairweather